Investigational drug · Phase 3
Huperzine A Controlled-Release
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Dementia.
Phase 3Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "Huperzine A Controlled-Release"
First trial start
2025
Aug 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Huperzine A Controlled-Release", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Dementia
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "Huperzine A Controlled-Release" as an intervention, largest first.
- Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypePivotal-lookingRecruiting
Wanbangde Pharmaceutical Group Co., LTDIndustry
NCT07066826 · 720 participants (planned) · Start Aug 29, 2025 · Primary completion Aug 15, 2028
Drug: Huperzine A Controlled-Release Tablets; Donepezil hydrochloride tablets and 1 more · For: Alzheimer Dementia
Sites: Beijing, China
- Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's DiseasePivotal-lookingStatus unknown
Shandong Luye Pharmaceutical Co., Ltd.Industry
NCT01282619 · 390 participants (planned) · Start May 2010 · Primary completion Jun 2012
Drug: Huperzine A; huperzine A and 1 more · For: Alzheimer's Disease
Sites: Shanghai, China
- Comparative Bioavailability Study of an Immediate Release and Controlled Release Oral Formulations of Huperzine AStatus unknown
Hadassah Medical OrganizationAcademic, hospital or other
NCT01136551 · 8 participants (planned) · Start Sep 2010 · Primary completion Jan 2011
Drug: Huperzine A · For: Healthy; Bioavailability
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.